The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.

Trial Profile

The relationship between IL6 and the kinetics of the ApoB-containing Lipoproteins in people with chronic inflammatory joint disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Acronyms apoB Kinetics; KALIBRA
  • Most Recent Events

    • 15 Sep 2017 Primary endpoint of change in fractional catabolic rate of LDL-associated apolipoprotein has been met, according to results published in the Annals of the Rheumatic Diseases.
    • 15 Sep 2017 Results published in the Annals of the Rheumatic Diseases
    • 12 Dec 2014 Planned End Date changed from 19 Apr 2015 to 11 Dec 2014 as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top